It is not recommended for self-medication, athletic performance enhancement, or veterinary use without proper authorization
In the CY 2024 OPPS/ASC final rule with comment period (88 FR 81586 through 81589), we explained that we believe we should begin to take into consideration the PCR of non-cancer hospitals based on the most recently available data for calculating the target PCR
Routes of Drug Administration Chapter 6 Giovannitti JA, Trapp LD (1991) Adult sedation: oral, rectal, IM, IV
No third-party batch reports have been uploaded for this product yet
References PubMed Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds Current Pharmaceutical Design (PubMed) Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract PMC Utilizing developmentally essential secreted peptides such as Thymosin Beta-4 for regenerative therapies Annals of the New York Academy of Sciences (PubMed) Thymosin beta 4 and wound healing: new ideas PMC Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review Johns Hopkins Arthritis Center How to give a subcutaneous injection PMC Subcutaneous drug delivery review: pharmacologic considerations ASIPP / Alternative Therapies in Health and Medicine Intra-articular injection of BPC-157 for multiple types of knee pain A4M Thymosin Beta-4 professional monograph PubMed Detection of thymosin beta-4 and related peptides in sport drug testing Journal of Physiology and Pharmacology (PubMed) BPC-157 activity at very low doses without toxicity in animal studies Expert Opinion on Biological Therapy (PubMed) Thymosin beta-4 and its role in wound healing CDC Vaccine administration: subcutaneous route (angle/site
stable for up to 24 months [16]
